Drug-drug interaction study of S-217622

JRCT ID: jRCT2031210595

Registered date:05/02/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: COVID-19
• Date of first enrollment: 19/02/2022
• Target sample size: 14
• Study type: Interventional
• Intervention(s): Oral administration of S-217622

Outcome(s)

Primary Outcome

Digoxin, Rosuvastatin, Metformin: Cmax, Tmax, AUC0-last, AUC0-inf, t1/2,z, lamdaz, MRT, CL/F, Vz/F
S-217622: Cmax, Tmax, AUC0-96
Adverse events, physical examination, laboratory tests, vital signs, 12-lead ECG

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: <= 55age old
• Gender: Both
• Include criteria: Japanese healthy adult male and female participants
• Exclude criteria: History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data

Related Information

• Primary Sponsor: Nagata Tsutae